TGF-beta1 gene polymorphisms in patients with end-stage heart failure

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Cytokine Signaling

Background:

• Transforming growth factor (TGF)-beta1 is implicated in heart diseases like atherosclerosis and idiopathic cardiomyopathy.
• Genetic variations in the TGF-beta1 gene, specifically leucine(10)-->proline and arginine(25)-->proline polymorphisms, influence its production levels.
• Investigating these polymorphisms' association with end-stage heart failure in dilated cardiomyopathy (CMP) and ischemic heart disease (IHD) is crucial.

Purpose of the Study:

• To determine if TGF-beta1 gene polymorphisms are linked to end-stage heart failure.
• To differentiate the association of TGF-beta1 polymorphisms in dilated CMP versus IHD.

Main Methods:

• Genomic DNA from heart transplant recipients (n=253) and controls (n=94) was analyzed.
• Sequence specific oligonucleotide probing (SSOP) was used to identify TGF-beta1 gene polymorphisms.
• Patient groups included dilated CMP (n=109) and IHD (n=144).

Main Results:

• A significant difference in TGF-beta1 codon 10 genotype distribution was observed among patients with IHD, dilated CMP, and controls (p=0.034).
• Dilated CMP patients showed distinct genotype distributions compared to IHD patients (p=0.044) and healthy controls (p=0.017).
• No significant difference in genotype distribution was found for the TGF-beta1 codon 25 polymorphism.

Conclusions:

• The leucine(10)-->proline (codon 10) polymorphism in the TGF-beta1 gene is associated with end-stage heart failure in dilated CMP.
• This specific TGF-beta1 polymorphism is not associated with ischemic heart disease.
• The findings suggest a role for TGF-beta1 in the pathogenesis of dilated cardiomyopathy.